NZ528039A

NZ528039A - Method for purifying 20(S)-camptothecin

Info

Publication number: NZ528039A
Application number: NZ528039A
Authority: NZ
Inventors: Rainer Sobotta; Armin Rapp
Original assignee: Boehringer Ingelheim Pharma
Priority date: 2001-02-15
Filing date: 2002-02-09
Publication date: 2006-02-24
Also published as: WO2002064597A2; PL202135B1; BR0207261A; HK1064092A1; EA200300837A1; EP1362051B1; CN1228340C; ES2246389T3; YU61403A; HRP20030654A2; EE200300389A; KR20030076674A; IL157148A0; CZ300671B6; JP2004521909A; NO20033614D0; ATE301124T1; EA005618B1; MXPA03007194A; CA2435372C

Abstract

The process for purifying 20(S)-camptothecine is described to comprise the following steps: (a) combining an aqueous base and a starting material containing 20(s)-camptothecine, thereby converting the lactone ring of the 20(S)-camptothecine into a carboxylate salt; (b) hydrogenating the resulting mixture in the presence of a transition metal catalyst; (c) acidifying the aqueous phase, thereby forming camptothecine crystals; (d) adding at least one polar aprotic solvent; and (e) separating off the camptothecine crystals. The starting material in step (a) is described to consist substantially of a mixture of the compounds of formula (I) wherein R1 denotes ethyl or vinyl; and be a natural plant product. Also disclosed is the process for preparing 20(S)-camptothecine of formula (I) wherein R1 denotes ethyl from a 20-vinyl-camptothecine of formula (I) wherein R1 denotes vinyl. This involves combining an aqueous base and the starting material containing 20-vinyl-camptothecine, to form a compound of formula (II). R1 denotes vinyl, and Met denotes a metal. Following this step, (b) to (e) described above are carried out.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 528039 01-1188-ff-Ko 1/111 Boehringer Ingelheim Pharma KG 10 75058fft.205 Process for purifying 20(S)-Camptothecine 5 The invention relates to a process for purifying 20(S)-camptothecine contaminated by a vinyl-camptothecine deriyative. Background to the invention 20(S)-camptothecine (20(S)-CPT) is a natural alkaloid of formula (I) 0) OH O wherein R1 denotes ethyl. 15 20(S)-CPT and its derivatives, being topoisomerase I inhibitors, have tumour-inhibiting properties (e.g. Giovanelle, B.C. et al., Cancer Research, 51: 302-3055,1991, European Patent applications EP 0 074 256, EP 0 088 642, US Patents US 4,473,692, US 4,545,880, US 4,604,463 and International Patent Application WO 92/05785). 20(S)-CPT can be obtained as a crude product from the Chinese tree Camptotheca acuminata (Nyssaceae) (Wall M. et al., J. Am. Chem. Soc. 88: 3888-3890, 1966) or from the Indian tree 20 Nothapodytes foetida (nimmoniana) (formerly known as: Mappie foetida Miers) (Govindachari, T.R. et al., Phytochemistry 11: 3529-3531, 1972), inter alia. These crude products, particularly the one obtained from Nothapodytes foetida, contain 20(S)-CPT contaminated by a CPT derivative of formula (I) wherein R1 denotes vinyl (20-vinyl-25 CPT). Traditionally, the crude products are purified by complex chromatographic methods or by converting the camptothecine into the aqueous phase and eliminating impurities by extraction -2- with water-insoluble solvents (e.g. WO 94/19353). However, contamination by 20-vinyl-CPT cannot be efficiently dealt with by these methods. The problem of the present invention is therefore to provide a process which allows the 20(S)-5 CPT starting product to be purified without using complex chromatographic methods, or which at least provides a useful alternative. Description of the invention Surprisingly, it has been found that 20(S)-CPT can be virtually completely freed from contamination with 20-vinyl-CPT by first treating the starting material with an aqueous base, 10 hydrogenating and subsequently acidifying it and then isolating the product. The invention thus relates to a process for purifying 20(S)-camptothecine which comprises the following steps: (a) combining an aqueous base and a starting material containing 20(S)-camptothecine, 15 thereby converting the lactone ring of the 20(S)-camptothecine into a carboxylate salt; (b) hydrogenating the resulting mixture in the presence of a transition metal catalyst; (c) acidifying the aqueous phase, thereby forming camptothecine crystals; (d) adding a polar aprotic solvent; and (e) separating off the camptothecine crystals. 20 The invention further relates to a process for preparing 20(S)-camptothecine of formula (]) wherein R1 denotes ethyl, from 20-vinyl-camptothecine of formula (I) wherein R1 denotes vinyl, which comprises the following steps: (a) combining an aqueous base and the starting material containing 20(S)-25 camptothecine, forming a compound of formula (II), wherein R1 denotes vinyl; and 01-1188-prio—Ko 3/11 -3- Met denotes a metal; (b) hydrogenating the resulting mixture in the presence of a transition metal catalyst; (c) acidifying the aqueous phase to form camptothecine crystals; / (d) adding at least one polar aprotic solvent; and (e) separating off the camptothecine crystals. Detailed description of the invention The term "starting material containing camptothecine " as used above and hereinafter refers to a contaminated material containing 20(S)-CPT, crude camptothecine, camptothecine-containing plant extracts, synthetic camptothecine, derivatives of camptothecine as described for example in International Patent Application WO 92/05785, or reaction products containing camptothecine. Preferably, the starting material is a natural crude product which is obtained in particular from Nothapodytes foetida. As a rule, it is a mixture of the compound of formula (I) wherein R1 denotes ethyl, and the compound of formula (I) wherein R1 denotes vinyl. It generally contains 0.9 to 1.5 wt.-%, preferably 1.0 to 1.4 wt.-% of the vinyl compound. In addition, the starting material may contain other camptothecine derivatives such as, for example, 9-methoxy-CPT, 10-methoxy-CPT, 11-methoxy-CPT, 10-hydroxy-CPT and 11-hydroxy-CPT. As a rule, the starting material contains up to 1 wt.-% of one or more of these additional CPT derivatives, particularly 0.2 to 0.8 wt.-% of 9-methoxy-CPT. The term "aqueous base" as used above and hereinafter in connection with step (a) of the purification process according to the invention relates to a base which generates enough hydroxide ions in the aqueous medium, preferably in pure water, to convert the lactone group of the camptothecine derivatives contained in the starting material completely into the corresponding hydroxycarboxylates. Metal hydroxides are preferred, particularly alkali metal or alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide or calcium hydroxide. Sodium hydroxide is most preferred. 01-1188-prio — Ko 4/11 -4- The metal hydroxide is preferably used in the form of a dilute aqueous solution, preferably in the form of a 1 to 25 %, particularly a 3 to 10 % aqueous solution. As a rule, sufficient metal hydroxide is used to make the camptothecine derivatives go completely into solution; preferably, 1 to 20 mol, more preferably 5 to 15 mol, particularly 7.5 to 12.5 mol of metal 5 hydroxide are used per 1 mol of starting material. In step (b) a transition metal catalyst, preferably a heterogeneous transition metal catalyst, particularly platinum, platinum oxide, nickel, palladium or rhodium on a carrier material such as activated charcoal or aluminium oxide is added to the resulting mixture. Palladium on 10 activated charcoal containing 1 to 15 wt.-%, preferably 2 to 10 wt.-%, particularly about 5 wt.-% of palladium is particularly preferred. The quantity of transition metal catalyst is selected so as to ensure total hydrogenation of the vinylic CPT derivative. Preferably, 0.01 to 0.50 parts by weight, particularly 0.02 to 0.10 15 parts by weight of transition metal catalyst (including carrier materials) are used, based on 1 part by weight of the starting material. The resulting mixture is subjected to the action of hydrogen gas, preferably at a temperature of - 20 °C to 100 °C, particularly 10 °C to 40 °C, most preferably at about room temperature. 20 The hydrogen pressure is not critical per se\ the hydrogenation is preferably carried out at | normal pressure or at slightly raised pressure, particularly at 0.9 to 5.0 bar, most preferably at about 1 bar. 25 Under these conditions, hydrogenation is generally complete within 1 to 20 hours, preferably 4 to 15 hours, particularly 6 to 10 hours. After the hydrogenation has ended, the transition metal catalyst is preferably eliminated by filtration, and the resulting reaction mixture is acidified in step (c). The acidification can be 30 done with an inorganic or organic acid. Preferred acids are inorganic acids such as HC1, HBr, HI, HNO3, H3PO4, H2SO4, or aliphatic carboxylic acids such as acetic acid and trifluoroacetic acid or mixtures of these acids, particularly concentrated hydrochloric acid. Using the chosen acid, the pH is adjusted to 3.0 to 6.0, preferably 3.5 to 5.0, particularly about 4.0 to 4.5. The -5- 10 15 reaction with the acid is generally carried out at a temperature of 0 °C to 100 °C, preferably 30 °C to 80 °C, particularly 50 °C to 60 °C. In a particularly preferred embodiment, acidification is carried out with 2 to 20 parts by weight, preferably 4 to 9 parts by weight, particularly 6 to 8 parts by weight of concentrated hydrochloric acid, based on 1 part by weight of starting material. Under the conditions described, lactonisation to form the CPT is generally complete within 10 to 180 minutes, preferably 15 to 60 minutes, particularly within about 30 minutes. The reaction mixture obtained by acidification is generally in the form of a pure suspension. To improve the crystallisation in step (d) one or more polar aprotic solvents are added thereto. Suitable solvents of this kind are preferably sulphoxides such as dimethylsulphoxide (DMSO) or amides and urea derivatives of formula R3 2 I R\ /Ns, 4 C R II O wherein R2 denotes hydrogen or a C1-4 alkyl group, particularly hydrogen or methyl; R3 and R4 independently of each other denote a C1-4 alkyl group, particularly methyl; or R2 and R3 together denote a -{CH2)ni- or a -NR5 -(CH2)n- group, while 20 R5 denotes a C1-4 alkyl group; m is 3 or 4, particularly 3; and n is 2 or 3, particularly selected from among N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidone (NMP), N,N-dimethylethylene urea (DMEU) and N,N-25 dimethylpropylene urea (DMPU) or mixtures of these solvents, most preferably DMF. As a rule, 10 to 100 parts by weight, preferably 20 to 80 parts by weight, particularly 30 to 50 parts by weight of the polar aprotic solvent are used, based on 1 part by weight of the starting material used. 15 NOV 2005 iX/Cr 01-1188-prio - Ko 6/11 The treatment with the polar aprotic solvent may be carried out at any desired temperature. The reaction mixture is preferably stirred at a temperature of 30 °C to 120 °C, particularly 80 to 100 °C and then slowly cooled to ambient temperature. 5 The CPT crystals thus obtained are easily separated from the liquid phase in step (e), preferably by decanting, centrifuging, spinning, squeezing out or filtration, particularly by filtration. As a rule, the CPT crystals thus obtained are washed with an alcohol, preferably methanol, 10 ethanol or isopropanol, particularly methanol, and dried. The advantage of the procedure according to the invention is the high space/time yield and the high yield and purity of the 20(S)-camptothecine produced, which is obtained without any chromatographic purification substantially free from contaminants containing vinyl groups. 15 The Examples that follow serve to illustrate some processes for purifying camptothecine carried out by way of example. They are intended only as possible methods given as examples, without restricting the invention to their content. 20 Example 1 10.45 g of a crude product containing camptothecine, obtained from Nothapodytes foetida, | containing 1.33 % of 20-vinyl-CPT and 0.47 % of 9-methoxy-CPT, is taken up in 260 ml of a 2 N sodium hydroxide solution and 0.6 g of palladium/activated charcoal (5 %) are added. The mixture is treated with hydrogen for 8 hours at ambient temperature under a pressure of 1 25 bar. Then the reaction mixture is filtered and combined at 50-60 °C with 80 ml of concentrated hydrochloric acid and adjusted to a pH of 4.0 to 4.5. 30 The suspension formed is combined with 400 ml of DMF and stirred for 2.5 hours at 90-100°C. The resulting suspension is slowly cooled to ambient temperature and filtered. The CPT crystals obtained are washed with 100 ml of methanol and dried at 55°C in vacuo. </div>

Claims

01-1188-prio — Ko 7/11 -7- 9.85 g (94.2 % of material put in) of 20(S)-camptothecine are obtained, containing less than 0.05 % of 20-vinyl-CPT and 0.11 % of 9-methoxy CPT. Example 2 5 10.45 g of a crude product containing camptothecine, obtained from Nothapodytes foetida, containing 1.33 % of 20-vinyl-CPT and 0.47 % of 9-methoxy-CPT is taken up in 260 ml of a 2 N sodium hydroxide solution and 0.6 g of palladium/activated charcoal (5 %) are added. The mixture is treated with hydrogen for 8 hours at ambient temperature under a pressure of 1 10 bar. Then the reaction mixture is filtered and combined at 50-60 °C with 300 ml of a 10% sulphuric acid and adjusted to a pH of 4.0 to 4.5. 15 The suspension formed is combined with 500 ml of DMF and stirred for 2.5 hours at 90-100°C. The resulting suspension is slowly cooled to ambient temperature and filtered. The CPT crystals obtained are washed with 100 ml of methanol and dried at 55°C in vacuo. 9.67 g (92.6 % of material put in) of 20(S)-camptothecine are obtained, containing 0.09 % of 20 9-methoxy CPT, the content of 20-vinyl-CPT being below the detection threshold. -8- Patent Claims 10 1. Process for purifying 20(S)-camptothecine, which comprises the following steps: (a) combining an aqueous base and a starting material containing 20(S)-camptothecine, thereby converting the lactone ring of the 20(S)-camptothecine into a carboxylate salt; (b) hydrogenating the resulting mixture in the presence of a transition metal catalyst; (c) acidifying the aqueous phase, thereby forming camptothecine crystals; (d) adding at least one polar aprotic solvent; and (e) separating off the camptothecine crystals. 15
2. Process for purifying 20(S)-camptothecine according to claim 1, wherein the starting material containing 20(S)-camptothecine is a natural plant product. 20
3. Process for purifying 20(S)-camptothecine according to claim 1 or claim 2, wherein the starting material containing 20(S)-camptothecine consists substantially of a mixture of the compounds of formula (I), (I) wherein R1 denotes ethyl or vinyl. O OH O 25
4. Process for purifying 20(S)-camptothecine according to one of the preceding claims, wherein the base in step (a) is sodium hydroxide. 5. Process for purifying 20(S)-camptothecine according to one of the preceding claims, wherein the mixture obtained in step (a) is hydro^^^ A/.Z I 5 MOV 2005 ■BJLCEJVEq presence of a palladium catalyst at a temperature of 0 °C to 100 °C and at a pressure of 0.5 bar to 5.0 bar. Process for purifying 20(S)-camptothecine according to one of the preceding claims, wherein the aqueous phase obtained in step (b) is treated with an acid selected from among HC1, HBr, HI, HN03, H3P04, H2S04, acetic acid and trifluoroacetic acid or mixture of these acids at a temperature of 30 °C to 80 °C. Process for purifying 20(S)-camptothecine according to one of the preceding claims, wherein the aqueous phase obtained in step (c) is treated with one or more polar aprotic solvents of formula R3 RVv II o wherein R2 denotes hydrogen or a C1-4 alkyl group; R3 and R4 independently of each other denote a C1-4 alkyl group; or R2 and R3 together denote a -(CH2)m- or a -NR
5-(CH2)n- group, while R5 denotes a C1-4 alkyl group; m is 3 or 4; and n is 2 or 3, at a temperature of 30 °C to 120 °C. Process for purifying 20(S)-camptothecine according to claim 7, wherein the polar aprotic solvent is selected from among N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidone (NMP), N,N-dimethylethylene urea (DMEU) and N,N-dimethylpropylene urea (DMPU) or mixtures of these solvents. Process for purifying 20(S)-camptothecine according to one of the preceding claims, wherein the 20(S)-camptothecine crystals in step (d) are separated off by filtration. INTELLECTUAL PROPERTY OFFICE OF N.Z. 15 NOV 2005 RE C EIV E D -10- 10. Process for preparing 20(S)-camptothecine of formula (I) wherein R1 denotes ethyl from a 20-vinyl-camptothecine of formula (1) wherein R1 denotes vinyl, which comprises the following steps: (a) combining an aqueous base and the starting material containing 20-vinyl-camptothecine, to form a compound of formula (II), .0 OH OMet CD) OH O wherein R1 denotes vinyl; and Met denotes a metal; (b) hydrogenating the resulting mixture in the presence of a transition metal catalyst; (c) acidifying the aqueous phase to form camptothecine crystals; (d) adding at least one polar aprotic solvent; and (e) separating off the camptothecine crystals. 11. 20(S)-camptothecine purified according to any one of claims 1 to 9. 12. 20(S)-camptothecine prepared according to claim 10. 13. A process according to claim 1 or claim 10, substantially as herein described with reference to example 1 or example 2. 14. A process according to any one of claims 1 to 10, substantially as herein described with reference to example 1 or example 2. BOEHRINGERINGELHEIM PHARMA GMBH & CO. KG By its Attorneys BALDWINS r^LECTUAL PROPERTY OF IV.z I 5 NOV 2005 -Received </div>